Luminex Corporation Company Profile (NASDAQ:LMNX)

Luminex Corporation trades on the NASDAQ under the ticker symbol "LMNX."

Luminex Corporation announced a quarterly dividend on Tuesday, September 12th. Stockholders of record on Friday, September 22nd will be given a dividend of $0.06 per share on Friday, October 13th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.20%. The ex-dividend date of this dividend is Thursday, September 21st. View Luminex Corporation's Dividend History.

Luminex Corporation (NASDAQ:LMNX) released its earnings results on Monday, August, 7th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.09 by $0.11. The firm earned $76.50 million during the quarter, compared to the consensus estimate of $75.45 million. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The firm's quarterly revenue was up 19.2% on a year-over-year basis. During the same period last year, the firm posted $0.33 EPS. View Luminex Corporation's Earnings History.

Luminex Corporation is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Luminex Corporation.

5 equities research analysts have issued 1-year target prices for Luminex Corporation's stock. Their predictions range from $18.00 to $27.00. On average, they anticipate Luminex Corporation's stock price to reach $21.25 in the next year. View Analyst Ratings for Luminex Corporation.

Here are some recent quotes from research analysts about Luminex Corporation stock:

• 1. According to Zacks Investment Research, "Luminex’s second quarter saw a strong top line, solid cash flow and soaring profits. The company also beat the Zacks Consensus Estimates on both lines. Luminex’s Assay business is likely to be its key growth driver over the long term. The company also witnessed favorable tidings at the regulatory front in the second quarter. In this regard, the recent CE-IVD mark for the ARIES Norovirus Assay,  the FDA approval of ARIES C. difficile Assay and the reimbursement approval of VERIGENE assay in Japan are noteworthy. Luminex is on the verge of completing its clinical study for Group A Strep and is close to submitting the same for FDA review. On the flipside, the company slashed its third-quarter revenue guidance. Luminex expects revenues at the segment to be impacted by funding challenges related to a multi-year bulk bead contract from a life science customer." (8/24/2017)
• 2. Piper Jaffray Companies analysts commented, "Luminex announced 4Q16 revenue of $72.3M, in line with preliminary results. Adj. EPS of $0.06 missed the Street's $0.13 estimate. Results in the quarter reflect strong consumables growth, somewhat offset by lighter instrument sales. Management reaffirmed FY17 revenue guidance of $295M-$305M and provided 1Q17 revenue guidance in line with the Street ($73M-$75M; Street: $74.2M). Revenue guidance appears achievable, but we believe shares are fairly valued. We remain Neutral with a $19 price target (was $20) based on ~2.1x FY18 EV/Rev (unchanged) on our revised estimates." (2/7/2017)

Some companies that are related to Luminex Corporation include Quidel Corporation (QDEL), Accelerate Diagnostics (AXDX), Mazor Robotics (MZOR), Natus Medical Incorporated (BABY), ABAXIS (ABAX), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), Accuray Incorporated (ARAY), ViewRay (VRAY), Corindus Vascular Robotics (CVRS), Cogentix Medical (CGNT), Cytosorbents Corporation (CTSO), Neovasc (NVCN), Harvard Bioscience (HBIO), IRIDEX Corporation (IRIX), Viveve Medical (VIVE) and Edap Tms S.A. (EDAP).

Luminex Corporation's management team includes the folowing people:

• G. Walter Loewenbaum II, Independent Chairman of the Board
• Nachum Shamir, President, Chief Executive Officer, Director
• Harriss T. Currie, Chief Financial Officer, Senior Vice President - Finance, Treasurer
• Richard W. Rew II, Senior Vice President, General Counsel, Secretary
• Todd C. Bennett, Senior Vice President - Global Sales and Customer Operations
• Nancy M. Fairchild, Senior Vice President - Human resources
• Tadd S. Lazarus M.D., Senior Vice President
• Randall Myers, Senior Vice President - Global Manufacturing and Quality
• Robert J. Cresci, Independent Director
• Stephen L. Eck, Independent Director

Luminex Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.15%), Vanguard Group Inc. (7.92%), Villere ST Denis J & Co. LLC (6.14%), Renaissance Technologies LLC (4.19%), Dimensional Fund Advisors LP (4.00%) and State Street Corp (2.43%). Company insiders that own Luminex Corporation stock include G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir, Robert J Cresci and Russell W Bradley. View Institutional Ownership Trends for Luminex Corporation.

Luminex Corporation's stock was sold by a variety of institutional investors in the last quarter, including Villere ST Denis J & Co. LLC, Acadian Asset Management LLC, Great Lakes Advisors LLC, Arrowstreet Capital Limited Partnership, GSA Capital Partners LLP, Eos Focused Equity Management L.P., Schwab Charles Investment Management Inc. and Goldman Sachs Group Inc.. Company insiders that have sold Luminex Corporation stock in the last year include G Walter Loewenbaum II, Kevin M Mcnamara and Robert J Cresci. View Insider Buying and Selling for Luminex Corporation.

Luminex Corporation's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Renaissance Technologies LLC, Citadel Advisors LLC, Algert Global LLC, Mitra Capital LLC, Hussman Strategic Advisors Inc. and Elk Creek Partners LLC. Company insiders that have bought Luminex Corporation stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex Corporation.

Shares of Luminex Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Luminex Corporation stock can currently be purchased for approximately $19.94.